Insider Selling: DexCom (NASDAQ:DXCM) EVP Sells $201,660.30 in Stock

DexCom, Inc. (NASDAQ:DXCM) EVP Sadie Stern sold 2,565 shares of the firm’s stock in a transaction dated Tuesday, October 27th. The stock was sold at an average price of $78.62, for a total value of $201,660.30. Following the completion of the transaction, the executive vice president owned 120,913 shares of the company’s stock, valued at approximately $9,506,180.06. The trade was a 2.08% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Sadie Stern also recently made the following trade(s):

• On Monday, September 28th, Sadie Stern sold 2,565 shares of DexCom stock. The shares were sold at an average price of $86.15, for a total value of $220,974.75.
• On Thursday, August 27th, Sadie Stern sold 2,565 shares of DexCom stock. The stock was sold at an average price of $88.37, for a total transaction of $226,669.05.

DexCom Stock Performance

Shares of NASDAQ DXCM opened at $82.29 on Friday. The company has a 50 day simple moving average of $85.82 and a two-hundred day simple moving average of $74.65. The stock has a market cap of $31.05 billion, a price-to-earnings ratio of 32.27, a PEG ratio of 1.34 and a beta of 1.48. The company has a current ratio of 1.73, a quick ratio of 1.43 and a debt-to-equity ratio of 0.47. DexCom, Inc. has a 12 month low of $54.11 and a 12 month high of $92.59.

DexCom (NASDAQ:DXCM) last released its quarterly earnings data on Thursday, October 29th. The medical device company reported $0.73 earnings per share for the quarter, topping analysts’ consensus estimates of $0.68 by $0.05. The firm had revenue of $1.34 billion for the quarter, compared to analyst estimates of $1.33 billion. DexCom had a net margin of 19.42% and a return on equity of 36.96%. The business’s quarterly revenue was up 11.1% compared to the same quarter last year. During the same quarter in the prior year, the business earned $0.61 earnings per share. As a group, analysts predict that DexCom, Inc. will post 2.64 earnings per share for the current year.

Hedge Funds Weigh In On DexCom

Several hedge funds and other institutional investors have recently made changes to their positions in DXCM. Ascentis Independent Advisors purchased a new stake in shares of DexCom in the first quarter valued at approximately $25,000. Latitude Advisors LLC acquired a new stake in shares of DexCom in the third quarter valued at approximately $32,000. Hilton Head Capital Partners LLC lifted its position in DexCom by 242.3% during the third quarter. Hilton Head Capital Partners LLC now owns 380 shares of the medical device company’s stock worth $33,000 after buying an additional 269 shares in the last quarter. Wellington Grp LLC lifted its position in DexCom by 778.7% during the first quarter. Wellington Grp LLC now owns 536 shares of the medical device company’s stock worth $34,000 after buying an additional 475 shares in the last quarter. Finally, Elevation Wealth Partners LLC lifted its position in DexCom by 61.0% during the third quarter. Elevation Wealth Partners LLC now owns 401 shares of the medical device company’s stock worth $35,000 after buying an additional 152 shares in the last quarter. Hedge funds and other institutional investors own 97.75% of the company’s stock.

Analyst Ratings Changes

A number of research firms have weighed in on DXCM. Robert W. Baird set a $105.00 price objective on DexCom in a research note on Friday, July 31st. TD Cowen restated a “buy” rating and issued a $95.00 target price on shares of DexCom in a research note on Friday, September 18th. Stifel Nicolaus set a $95.00 target price on DexCom and gave the stock a “buy” rating in a report on Friday, July 31st. Truist Financial set a $102.00 price target on DexCom and gave the company a “buy” rating in a research report on Friday, September 18th. Finally, Wall Street Zen upgraded DexCom from a “hold” rating to a “buy” rating in a research report on Sunday, September 6th. Two investment analysts have rated the stock with a Strong Buy rating, twenty have issued a Buy rating and two have issued a Hold rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Buy” and an average target price of $92.91.

Key Stories Impacting DexCom

Here are the key news stories impacting DexCom this week:

• Positive Sentiment: Quarterly results exceeded expectations. DexCom reported revenue of approximately $1.34 billion, up 11.1% year over year, and adjusted earnings of $0.73 per share, surpassing analyst estimates of $0.68. U.S. revenue grew 14%, supported by demand for its continuous glucose monitoring products and adoption of the G7 15 Day system. DexCom Stock Up on Q3 Earnings & Revenue Beat, Margins Rise
• Positive Sentiment: Margins improved materially. Non-GAAP operating margin reached 25.3%, while gross profit increased 18.2% and operating profit rose 34.9% year over year. The stronger earnings profile likely reinforced confidence in DexCom’s growth and cost management. DexCom Q3 2026 Earnings
• Positive Sentiment: Full-year outlook was raised. Management increased the midpoint of its 2026 revenue forecast to a range of $5.20 billion to $5.25 billion and lifted operating-margin and adjusted-EBITDA-margin guidance.
• Positive Sentiment: Shareholder returns received a boost. DexCom authorized a new $1.0 billion share buyback, which could support earnings per share and signal management’s confidence in cash generation. DexCom Announces $1 Billion Equity Buyback
• Positive Sentiment: Analyst sentiment improved. Barclays raised its price target from $115 to $120 while maintaining an “overweight” rating, citing potential upside following the results and improved outlook.
• Neutral Sentiment: Institutional ownership data showed substantial buying by several funds, including Invesco and Arrowstreet, but also significant reductions by other investors. This suggests mixed positioning rather than a clear institutional consensus.
• Negative Sentiment: Insider selling remains a cautionary signal. DexCom insiders reported 26 open-market sales and no purchases over the past six months. A recent sale by EVP Sadie Stern was made under a pre-arranged Rule 10b5-1 plan, reducing its predictive value, but the broader pattern may limit enthusiasm among some investors.

About DexCom

DexCom, Inc develops and commercializes continuous glucose monitoring (CGM) systems for people with diabetes. Its devices use a small wearable sensor to measure glucose levels in real time and transmit readings to compatible smartphones, receivers, smartwatches, and other connected devices, helping users monitor glucose trends and make informed decisions about their health.

The company’s product portfolio includes the Dexcom G7 and Dexcom G6 CGM systems, as well as Dexcom ONE and Dexcom ONE+ products offered in select markets.